Business
Neurolens debuts official rebrand as Newton
Maker of the first and only therapeutic lenses clinically proven to relieve eye misalignment symptoms announces next chapter in its eyecare journey.
Research
New data reinforces XIIDRA's eye dryness relief among CL wearers
Open-label study evaluated effectiveness of lifitegrast 5%, noting significant improvements in end-of-day dryness and discomfort in just 2 weeks.
Pipeline
Opus Genetics doses first patient in LYNX-3 phentolamine 0.75% study
Third phase 3 trial is evaluating the PF-based eye drop for chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
Products
Alcon launches first fully personalized LASIK treatment
The wavelight plus includes ray-tracing technology to create a 3D eye model for a fully-tailored treatment approach for refractive surgery.
Business
Topcon invests in Senseye's ocular biomarker-based mental health platform
First app of its kind utilizes the eye as a non-invasive window to the brain to identify neuropsychiatric conditions—in just 15 minutes.
Products
Bausch + Lomb launches ASANA gas permeable lenses
Latest addition to the company’s GP lens portfolio is a versatile lens custom designed to provide advanced visual acuity and all-day shape maintenance.
Research
What factors impact visual acuity in intermediate AMD?
Study identifies three key features that impact visual acuity in patients with intermediate AMD.
Products
Scope introduces OPTASE HYLO FORTE dry eye drops
Artificial tear is formulated with active glycerin for moderate-to-severe dry eye disease, offering extra moisture and a protective cushion for long-lasting relief.
Business
OpZira launches with LumiThera diagnostic product line
Spin-off company official forms following Alcon-LumiThera acquisition to offer two ophthalmic products: the AdaptDx Pro and NOVA Vision Testing System.
Business
Alcon officially purchases LumiThera
Acquisition of the Valeda Light Delivery System includes plans to expand commercial market availability in 2026.
Pipeline
FDA grants RMAT designation to Nanoscope for Stargardt gene therapy
MCO-010 optogenetic therapeutic has potential to become first-ever treatment for Stargardt; phase 3 trial expected to kick off in Q4 2025.
Products
VirtuaLens launches with VR-based IOL simulator
New company debuts a first-of-its-kind, customizable VR simulator for patients to try out lenses ahead of surgery in immersive 3D lifestyle scenarios.
Products
Unique anterior stromal puncture device targets RCEs
VEO Ophthalmics and Plexitome Medical’s partnership includes commerical launch of a new ASP method that allows treatment in the optical axis—without scarring.
Research
Researchers identify long-term risk factors of VF progression in glaucoma
Study outlines key considerations for treating patients with primary angle-closure disease.
Pipeline
Nicox reports positive phase 3 data on NCX 470 glaucoma eye drop
Topline results from the Denali trial support a future NDA submission for the nitric oxide-donating bimatoprost formulation to lower IOP.
Products
New World Medical debuts new Ahmed ClearPath glaucoma device
Latest model of the non-valved glaucoma drainage device for IOP reduction features a smaller tube lumen, offering surgeons more options and flexibility.
Products
identifeye HEALTH launches AI-based retinal screening platform
The FDA-registered, compact, app-based portable system is designed to detect early signs of ocular and systemic disease in point-of-care settings.
Pipeline
Outlook Therapeutics receives second FDA CRL over wet AMD BLA
Agency rejects submission of bevacizumab-vikg for a second time, citing a single issue with the application: a lack of effectiveness data.
Research
Are prostaglandins really the most effective glaucoma therapy?
Prostaglandin analogs were most effective when used in combination with other topical medications.
Research